40 results about "Proline rich" patented technology

A new approach in the field of plant gums is described which presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabinogalactan-proteins (AGPs). The expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum arabic glycoprotein (GAGP), is taught in host cells, including plant host cells.

The invention relates to a method for linking two or more molecular substances, by means of adapter segments, which bring about a targeted interaction based upon the affinity of proline-rich amino acid sequences and protein domains of the type WW.

A new approach in the field of plant gums is described which presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabinogalactan-proteins (AGPs). The expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum arabic glycoprotein (GAGP), is taught in host cells, including plant host cells.

A new approach in the field of plant gums is described which presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabino-galactan proteins (AGPs). The expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum arabic glycoprotein (GAGP), is taught in host cells, including plant host cells.

A new approach in the field of plant gums is described which presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabinogalactan-proteins (AGPs). The expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum arabic glycoprotein (GAGP), is taught in host cells, including plant host cells.

Present invention relates to an immunologically active nonapeptide fragments of a proline-rich polypeptide isolated from mammalian colostral fluids for treatment of viral and non-viral diseases or diseased conditions, a method and a system for processing mammalian colostral fluids for isolating target peptides and proteins, a pharmaceutical formulation containing such peptides and its use for the treatment of viral diseases or diseased conditions. The product comprises proline-rich polypeptide of immuno regulatory properties. The method of processing includes, steps of passing bodies fluids, such as, mammalian colostral fluids through at least one ion exchange column such as an anionic resin and / or a cationic resin. The ion exchange column can be selected to retained large particles at a first pH level selected to remove such large particles at a maximum fluid pressure of 30 pounds per square inch (psi), preferably less than 10 psi.

The invention relates to a PRR11 (Proline-rich protein 11, PRR11) gene, a coded protein and the application of the gene and the protein in diagnosis and treatment of tumor.

The present invention provides regulatory polynucleotide molecules isolated from plant proline rich protein genes and linked to a viral enhancer molecule. The invention further discloses compositions, polynucleotide constructs, transformed host cells, transgenic plants and seeds containing the regulatory polynucleotide sequences, and methods for preparing and using the same.

The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.

The invention relates to compounds of general formula (I), which can be used particularly as structural mimetics of proline-rich peptides and are therefore capable of binding PRM binding domains (proline-rich motif binding domains) of proteins. The invention also relates to the use of said compounds as pharmaceutical active agents and the use of these pharmaceutical active agents for treating bacterial diseases, neurodegenerative diseases and tumors.

This invention relates to a regulatory element useful for genetically engineering sugarcane or other monocots, to the transformation of the monocots with the regulatory element so that they produce a desired product, and to the regeneration of the monocots transformed with the regulatory element. In particular the present invention provides a nucleic acid encoding the promoter of a sugarcane proline rich protein as shown in Seq ID #3.

Polypeptide sequences for inducing recombinant protein bodies are described. The sequences comprise a polyproline II (PPII) structure and / or a proline-rich sequence between two cysteine residues on either end. Recombinant protein bodies are useful for protein production because they allow for simple and efficient purification of high quantities of recombinant protein. In addition, other methods of using recombinant protein bodies, for example, in vaccination and food products, are also described.

The invention discloses a salivary proline-rich protein bionic anti-caries functional polypeptide, and a polypeptide derivative or a pharmaceutically acceptable salt, the amino acid sequence of the salivary proline-rich protein bionic anti-caries functional polypeptide is shown in SEQ ID NO.1, the polypeptide is one polypeptide segment of a neutral proline-rich protein 2 in saliva, has a capability of promoting the nucleation of hydroxyapatite, promotes remineralization of demineralized enamel, and reduces caries depth of the demineralized enamel and the mineral loss; the polypeptide is excellent in structure stability and has no obvious cytotoxicity, and compared with a natural proline-rich protein, the polypeptide is low in molecular weight, can be artificially synthesized, is low in cost, is easy to purify, and has a higher potential of a patent medicine. The invention further provides an application of the polypeptide to the preparation of an anti-caries medicine.

The present invention provides a method for improving salt tolerance of a plant so as to enable the plant to be cultivated under a high salt concentration condition. The present invention discloses a method for improving salt tolerance of a plant, including suppressing or inhibiting a function of PERK13 (Proline-rich extensin-like receptor kinase 13) in a plant; the method for improving salt tolerance of a plant, wherein an antagonist of PERK13 is brought into contact with a root of the plant; the method for improving salt tolerance of a plant, wherein the antagonist is one or more species of microorganisms or a secretion therefrom; and the method for improving salt tolerance of a plant, wherein the suppression of the function of the PERK13 is carried out by suppressing expression of PERK13 gene, or the inhibition of the function of the PERK13 is carried out by inhibiting expression of PERK13 gene.

The invention discloses a wheat proline-rich protein Tazmh122, a coding gene and application thereof. The wheat proline-rich protein Tazmh122 has an amino acid sequence shown as SEQ ID NO:2. The nucleotide sequence of the gene coding the wheat proline-rich protein Tazmh122 is shown as SEQ ID NO:1. The invention provides the new wheat proline-rich protein Tazmh122 and its coding gene. By a genetic engineering method, the wheat proline-rich protein Tazmh122 coding gene provided by the invention is transferred into wheat to improve the thousand kernel weight of wheat. The gene is the endogenous gene of the grain crop wheat itself, therefore, over-expression of the gene has no influence to the food safety of plants, and the gene can be applied in crop breeding.

The invention relates to the technical fields of gene engineering and the biomedicine of protein transduction, in particular to fusion proteins of a human Scurfin span with a membrane penetration sequence, a Forkhead removing domain human Scurfin fragment and a proline-rich removing domain human Scurfin fragment and a preparation method. The fusion proteins of the human Scurfin span with the membrane penetration sequence, the Forkhead removing domain human Scurfin fragment and the proline-rich removing domain human Scurfin fragment respectively have amino acid sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention adopts a mode of constructing PTD-hScurfin to obtain the fusion proteins for the first time, transduces a target protein into Jurkat T and peripheral CD4+CD25-T cells by the direct mediation and fusion of a protein membrane penetration structure field to obtain Treg in mass, and breaks through the bottleneck constraining Treg application in the hope of being applied to the repulsion-resisting treatment of clinical organ transplantation finally.

The present invention provides a method for improving salt tolerance of a plant so as to enable the plant to be cultivated under a high salt concentration condition. The present invention discloses a method for improving salt tolerance of a plant, including suppressing or inhibiting a function of PERK13 (Proline-rich extensin-like receptor kinase 13) in a plant; the method for improving salt tolerance of a plant, wherein an antagonist of PERK13 is brought into contact with a root of the plant; the method for improving salt tolerance of a plant, wherein the antagonist is one or more species of microorganisms or a secretion therefrom; and the method for improving salt tolerance of a plant, wherein the suppression of the function of the PERK13 is carried out by suppressing expression of PERK13 gene, or the inhibition of the function of the PERK13 is carried out by inhibiting expression of PERK13 gene.

The invention relates to the Proline-Rich Polypeptide complex (PRP) derived from the mammalian colostrum for use in the treatment of the disorders and conditions related to the alterations of the Brain-Derived Neurotrophic Factor level as well as modulation thereof, particularly disorders and conditions wherein therapeutic strategy is based on the increasing of the BDNF concentration in blood.The PRP complex is postulated to be used for nutrition of adults, young children / babies and infants to promote and preserve the proper development and function of both immune and nervous system. PRPs may be used for supplementation of modified milk and infant milk formulae to make it closer to breast milk.

The present invention relates to chemical compounds that can in particular be used as structural mimetics of proline-rich peptides. The compounds of the present invention are capable of selectively inhibiting ena / VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical agents and to the use of the pharmaceutical agents to treat tumor diseases. The chemical compounds of the present invention can significantly inhibit the chemotaxis and motility of invasive tumor cells and can therefore be used in the treatment and / or prevention of tumor metastases.

The invention provides a beverage cold turbidity preventing method. According to the method, an enzyme preparation is added into a beverage to be treated, the enzyme preparation is prepared from the main ingredients of one or two of dipeptidylpeptidase IV (DPPIV) and specific proline endoprotease, the enzymolysis adding amount of the dipeptidylpeptidase IV is 0.1 to 50 ppm, and a treating temperature is kept at -10 to 40 DEG C. A dipeptidylpeptidase IV and / or specific proline endoprotease enzymolysis method is utilized to degrade proline-rich protein which is prone to cause cold turbidity, sothat protein, polyphenol and polymers thereof are prevented from generating precipitate; thus, the purposes of preventing cold turbidity and prolonging product shelf life are achieved, and nutritionalingredients of the beverage can be ensured to be comprehensively kept.

The present invention relates to a binding molecule, in particular an antibody or binding fragment thereof, capable of activating FXII, which binds to the proline rich domain of FXII. In particular, the invention is directed to FXII activating antibodies or binding fragments thereof which binds to the proline rich domain of FXII. The invention also encompasses the use of the binding molecule directed to the proline rich domain of FXII as blood coagulation activator, e.g. in diagnostic blood coagulation tests. Corresponding methods and blood coagulation test are also encompassed.

The invention provides a bovine colostrum powder, a preparation method and a preparation thereof, and an application thereof in the preparation of a tumor treatment drug, and relates to the field of antitumor drugs. The bovine colostrum powder contains immunoglobulin, lactoferrin, proline-rich polypeptides and various other bioactive components, fully utilizes the synergistic effects among the bioactive components of bovine colostrum, and has high nutritional values and medicinal values. The bovine colostrum powder is obtained by sequentially removing fats, macromolecular proteins, small molecular impurities and water from the bovine colostrum, so the original characteristics of all the bioactive components are retained, the bovine colostrums is maximally used, and the utilization rate ofthe bovine colostrums is improved. The preparation prepared from the bovine colostrum powder has the advantages of low cost, convenience in taking, safety and no toxic or side effects, contains various bioactive components, can regulate the immune balance of the human body and improve the cell activity, can be used for treating tumors, and can be applied to the production of the tumor treatment drugs.

rAAV compositions useful for preventing the toxicity associated with organophosphate exposure are provided herein. The rAAV co-express a human butyrylcholinesterase and a proline-rich peptide. Each the esterase and the peptide may have an exogenous signal sequence. Also provided are compositions, e.g., aqueous liquid suspensions containing the rAAV.